Department of Cancer Biology, Wake Forest University Health Sciences, Winston-Salem, NC 27157, USA.
Molecules. 2018 Mar 12;23(3):638. doi: 10.3390/molecules23030638.
The interest in zirconium-89 (Zr) as a positron-emitting radionuclide has grown considerably over the last decade due to its standardized production, long half-life of 78.2 h, favorable decay characteristics for positron emission tomography (PET) imaging and its successful use in a variety of clinical and preclinical applications. However, to be utilized effectively in PET applications it must be stably bound to a targeting ligand, and the most successfully used Zr chelator is desferrioxamine B (DFO), which is commercially available as the iron chelator Desferal. Despite the prevalence of DFO in Zr-immuno-PET applications, the development of new ligands for this radiometal is an active area of research. This review focuses on recent advances in zirconium-89 chelation chemistry and will highlight the rapidly expanding ligand classes that are under investigation as DFO alternatives.
在过去十年中,由于锆-89(Zr)可标准化生产、半衰期长(78.2 小时)、适合正电子发射断层扫描(PET)成像的衰变特性,以及在各种临床和临床前应用中的成功使用,人们对其作为正电子发射放射性核素的兴趣大大增加。然而,要在 PET 应用中有效地使用它,它必须稳定地结合到靶向配体上,而最成功使用的 Zr 螯合剂是去铁胺 B(DFO),它以铁螯合剂去铁胺(Desferal)的形式在商业上可用。尽管 DFO 在 Zr-免疫 PET 应用中很普遍,但开发这种放射性金属的新配体仍然是一个活跃的研究领域。这篇综述重点介绍了锆-89 螯合化学的最新进展,并强调了正在研究作为 DFO 替代品的快速扩展的配体类别。